Vanguard Group Inc. Has $4.08 Million Holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Posted by MarketBeat News on Aug 19th, 2024

Vanguard Group Inc. reduced its stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) by 94.8% during the first quarter, HoldingsChannel reports. The firm owned 341,300 shares of the company’s stock after selling 6,219,100 shares during the quarter. Vanguard Group Inc.’s holdings in Outlook Therapeutics were worth $4,075,000 at the end of the most recent reporting period.

Separately, Rosalind Advisors Inc. acquired a new stake in Outlook Therapeutics in the first quarter valued at approximately $3,723,000. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Price Performance

Shares of OTLK stock opened at $7.71 on Monday. Outlook Therapeutics, Inc. has a one year low of $4.00 and a one year high of $29.20. The business’s 50 day simple moving average is $7.68 and its 200 day simple moving average is $8.05. The stock has a market capitalization of $180.49 million, a PE ratio of -0.68 and a beta of 0.71.

Analysts Set New Price Targets

Want More Great Investing Ideas?

OTLK has been the subject of a number of research reports. Chardan Capital reiterated a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Thursday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.55.

Read Our Latest Stock Report on Outlook Therapeutics

About Outlook Therapeutics

(Free Report)

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.